Under Buechler's leadership, Biosite commercialized the first immunoassay to measure B-type natriuretic peptide (BNP), which in turn revolutionized how physicians diagnose and evaluate patients with congestive heart failure. In 2015, the University of California, San Diego, honored him for this specific advancement in cardiovascular care.
Prior to forming Biosite, Buechler was a senior research scientist at Hybritech Inc., where he was the project leader for cardiac biomarker assays. Additionally, he was responsible for the design and synthesis of reagents for use in the first rapid, visual pregnancy test, the ICON hCG.
Buechler is currently the chairman of the board of Quidel Corp. and is a board member of the Rady Children’s Institute for Genomic Medicine and the UC San Diego Sulpizio Cardiovascular Center Directors’ Council. He is the past chairman of the board for Sequenom Inc. and was on the boards of Edico Genome Inc., Sotera Wireless Inc., and Astute Medical Inc. He is a proud Hoosier and is honored to remain active in the IU alumni community.